Selank 10mg

Research applications

• Rodent anxiety-related behavioural assays (elevated plus maze, open field)
• Immune cell signalling and tuftsin-pathway research
• Gene expression studies of monoamine and neurotrophic pathways
• Comparative structure-activity research alongside Semax

What the literature reports on Selank

Selank was developed as a stabilised analogue of tuftsin, a naturally occurring immunomodulatory peptide, using the same Pro-Gly-Pro stabilisation strategy applied to Semax. This shared design has made the two peptides a common comparative pair in the pharmacology literature, particularly in studies examining structure-activity relationships within short proline-containing peptides.

Behavioural pharmacology

Rodent studies using standard anxiety-related behavioural assays, including the elevated plus maze and open-field tests, have reported changes in exploratory and avoidance behaviour following Selank administration. This body of work is generally discussed in the literature alongside research into GABAergic and monoaminergic signalling pathways.

Immune and gene expression research

Because Selank derives from tuftsin, a peptide with documented roles in immune cell signalling, a portion of the research literature has examined its effects on cytokine expression and leukocyte activity in animal and in vitro models. Separately, gene expression studies have reported changes in the transcription of enzymes involved in monoamine metabolism, a line of research often cited alongside the behavioural pharmacology findings.

Comparative research with Semax

Because Selank and Semax share a design lineage but differ in their core sequence, researchers frequently study them side by side to separate sequence-specific effects from the shared Pro-Gly-Pro stabilisation motif. A detailed comparison of the published findings for both peptides is available in the Semax vs Selank guide, and the broader Semax literature is indexed on the Semax research pillar.

Stability and analytical research

As with Semax, a body of analytical chemistry literature has examined Selank's stability under various storage and reconstitution conditions, characterising degradation pathways relevant to laboratory handling. This research directly informs the recommended storage practice for lyophilised and reconstituted material, detailed further in the peptide reconstitution and storage guide.

Dose-response and pharmacokinetic research

Pharmacokinetic studies in animal models have characterised Selank's absorption and clearance profile following intranasal and parenteral routes of administration in the research literature, reporting a short plasma half-life consistent with other short, unmodified peptides. This pharmacokinetic profile is a recurring variable considered when researchers design dose-response protocols for behavioural and immunological assays involving Selank.

Laboratory handling

Each vial of lyophilised Selank should be stored at -20°C prior to reconstitution and protected from light and humidity. As with other short peptides in this catalogue, standard laboratory practice is to reconstitute with bacteriostatic water or sterile water for injection, introduced slowly along the vial wall rather than directly onto the lyophilised cake.

• Lyophilised powder: store at -20°C, protected from light, until reconstitution.
• Reconstitution: introduce diluent slowly along the vial wall; avoid vigorous shaking.
• Post-reconstitution: 2-8°C for short-term laboratory use; avoid repeated freeze-thaw cycles.
• Each batch ships with a certificate of analysis confirming ≥99% purity by HPLC and identity by mass spectrometry.

See the peptide reconstitution and storage guide for a full laboratory protocol reference. This product is intended for laboratory research use only.